TELAPREVIR- BASED THERAPY IN G1 HCV-INFECTED PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN: REALIZE TRIAL FINAL RESULTS

被引：0

作者：

Foster, G. ^{[1
]}

Zeuzem, S. ^{[2
]}

Andreone, P. ^{[3
]}

Pol, S. ^{[4
,5
]}

Lawitz, E. ^{[6
]}

Diago, M. ^{[7
]}

Roberts, S. ^{[8
]}

Focaccia, R. ^{[9
]}

Younossi, Z. ^{[10
]}

H, A. ^{[11
]}

Heeswijk, R. V. ^{[12
]}

de Meyer, S. ^{[12
]}

Luo, D. ^{[13
]}

Picchio, G. ^{[13
]}

Beumont, M. ^{[12
]}

机构：

[1] Queen Mary Univ London, Inst Cell & Mol Sci, London, England

[2] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany

[3] Univ Bologna, Bologna, Italy

[4] Univ Paris 05, INSERM, U567, Paris, France

[5] Hop Cochin, AP HP, F-75674 Paris, France

[6] Alamo Med Res, San Antonio, TX USA

[7] Hosp Gen Valencia, Valencia, Spain

[8] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia

[9] Emilio Ribas Infect Dis Inst, Sao Paulo, Brazil

[10] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA

[11] Med Univ Warsaw, Warsaw, Poland

[12] Tibotec BVBA, Beerse, Belgium

[13] Tibotec Inc, Titusville, NJ USA

来源：

GUT | 2011年 / 60卷

关键词：

D O I：

10.1136/gutjnl-2011-300857b.3

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OP03

引用

页码：A50 / A51

页数：6

共 50 条

[1] Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results
Mullhaupt, Beat
Zeuzem, Stefan
Andreone, Pietro
Pol, Stanislas
Lawitz, Eric
Diago, Moises
Roberts, S.
Focaccia, Roberto
Younossi, Zobair
Foster, Graham
Horban, Andrzej
Pockros, Paul. J.
Van Heeswijk, Rolf
de Meyer, Sandra
Luo, Donghan
Picchio, Gaston
Beumont, Maria
SWISS MEDICAL WEEKLY, 2011, 141 : 6S - 6S
[2] Telaprevir-Based Regimen in Genotype 1 Hepatitis C Virus-Infected Patients With Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results
Pockros, Paul
Zeuzem, Stefan
Lawitz, Eric J.
Younossi, Zobair M.
Andreone, Pietro
Pol, Stanislas
Diago, Moises
Roberts, Stuart K.
Focaccia, Roberto
Foster, Graham
Horban, Andrzej
van Heeswijk, Rolf
De Meyer, Sandra
Luo, Don
Picchio, Gaston
Beumont-Mauviel, Maria
GASTROENTEROLOGY, 2011, 140 (05) : S898 - S898
[3] REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN
Zeuzem, S.
Andreone, P.
Pol, S.
Lawitz, E. J.
Diago, M.
Roberts, S.
Focaccia, R.
Younossi, Z. M.
Foster, G. R.
Horban, A.
Pockros, P. J.
Van Heeswijk, R.
de Meyer, S.
Luo, D.
Picchio, G.
Beumont, M.
JOURNAL OF HEPATOLOGY, 2011, 54 : S3 - S3
[4] SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR
Berg, T.
McHutchison, J. G.
Adda, N.
Poordad, F.
Shiffman, M. L.
Ferenci, P.
Heathcote, J.
Pawlotsky, J. -M.
Zeuzem, S.
Reesink, H.
Dusheiko, G.
Martin, E.
Alexanderian, D.
George, S.
Muir, A. J.
JOURNAL OF HEPATOLOGY, 2010, 52 : S2 - S2
[5] Final Results of a Rollover Study Assessing Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic HCV Patients With Well-Characterized Null Response, Partial Response, Viral Breakthrough, or Relapse After Prior PR Treatment
Muir, Andrew J.
Poordad, Fred
Adda, Nathalie
Shiffman, Mitchell L.
Berg, Thomas
Ferenci, Peter
Heathcote, E. Jenny
Pawlotsky, Jean-Michel
Zeuzem, Stefan
Reesink, Henk W.
Dusheiko, Geoffrey M.
Martin, Emily C.
Alexanderian, David
George, Shelley
McHutchison, John
GASTROENTEROLOGY, 2010, 138 (05) : S782 - S783
[6] Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1
Akuta, Norio
Suzuki, Fumitaka
Seko, Yuya
Kawamura, Yusuke
Sezaki, Hitomi
Suzuki, Yoshiyuki
Hosaka, Tetsuya
Kobayashi, Masahiro
Kobayashi, Mariko
Saitoh, Satoshi
Arase, Yasuji
Ikeda, Kenji
Kumada, Hiromitsu
JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (07) : 1097 - 1105
[7] Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1
Serfaty, Lawrence
Forns, Xavier
Goeser, Tobias
Ferenci, Peter
Nevens, Frederik
Carosi, Giampiero
Drenth, Joost P.
Lonjon-Domanec, Isabelle
DeMasi, Ralph
Picchio, Gaston
Beumont, Maria
Marcellin, Patrick
GUT, 2012, 61 (10) : 1473 - 1480
[8] Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Feld, Jordan J.
Jacobson, Ira M.
Jensen, Donald M.
Foster, Graham R.
Pol, Stanislas
Tam, Edward
Jablkowski, Maciej
Berak, Hanna
Vierling, John M.
Yoshida, Eric M.
Perez-Gomez, Hector R.
Scalori, Astrid
Hooper, Gregory J.
Tavel, Jorge A.
Navarro, Mercidita T.
Shahdad, Saba
Kulkarni, Rohit
Le Pogam, Sophie
Najera, Isabel
Eng, Simon
Lim, Chin Yin
Shulman, Nancy S.
Yetzer, Ellen S.
JOURNAL OF HEPATOLOGY, 2015, 62 (02) : 294 - 302
[9] Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
Vierling, John M.
Davis, Mitchell
Flamm, Steven
Gordon, Stuart C.
Lawitz, Eric
Yoshida, Eric M.
Galati, Joseph
Luketic, Velimir
McCone, Jonathan
Jacobson, Ira
Marcellin, Patrick
Muir, Andrew J.
Poordad, Fred
Pedicone, Lisa D.
Albrecht, Janice
Brass, Clifford
Howe, Anita Y. M.
Colvard, Lynn Y.
Helmond, Frans A.
Deng, Weiping
Treitel, Michelle
Wahl, Janice
Bronowicki, Jean-Pierre
JOURNAL OF HEPATOLOGY, 2014, 60 (04) : 748 - 756
[10] Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
Song, Ze-Zhou
JOURNAL OF HEPATOLOGY, 2015, 63 (03) : 769 - 770

← 1 2 3 4 5 →